Carbon monoxide and Parkinson’s disease research

Medical research has explored a potential link between carbon monoxide exposure and a reduced risk of Parkinson’s disease. An initial study involving over 500,000 Chinese adults over 12 years suggested that higher levels of carbon monoxide in exhaled breath were associated with lower Parkinson’s risk, even in non-smokers. This finding suggests the protective effect might be attributed to the compound itself rather than the act of smoking.

Subsequent reports have contextualized these findings within broader global health data. While research in JAMA Neurology indicates that regular tobacco use is associated with a roughly 30% lower risk of developing Parkinson’s, researchers emphasize that smoking remains a major cause of lung cancer, heart disease, and stroke.

Additionally, data analyzed by the Institute for Health Metrics and Evaluation highlights the significant global impact of secondhand smoke, noting that billions of people were exposed in 2023, contributing to millions of deaths and significant loss of healthy life years. Experts caution that the observed association between carbon monoxide and Parkinson’s does not imply that increasing exposure is safe, as the gas remains highly dangerous to human health.